Georg A. Feichtinger

Dr. Georg A. Feichtinger was leading the molecular biology laboratory at the Ludwig Boltzmann at the University of Vienna, where he obtained his doctoral degree for the thesis 'Non-viral transient gene therapy for bone regeneration”, from 2008 – 2013. He also had an educational role as a visiting lecture at both the University of Applied Sciences Technikum, and later the University College London after his joining the Department of Oral Biology at the University of Leeds. At present, Dr. Feichtinger is continuing his research interest in the gene therapies meanwhile regenerative medicine and biotechnology, while he mainly works on the non-viral in vivo gene delivery gradients and smart gene-activated matrix biomaterials for tissue regeneration; the foundation of the his investigation approaches is the idea that modern, innovative therapeutics should provide minimally-invasive, biomimetic signalling cues at the site of implantation to augment and complement the endogenous regenerative capacity of the host.

Lab Information

Department of Oral Biology, The University of Leeds

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Regenerative Medicine 0 Gene Therapy 0 ATMP 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (1)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Raftery RM, Mencía-Castaño I, Sperger S, Chen G, Cavanagh B, Feichtinger GA, Redl H, Hacobian A, O'Brien FJ. 2018. Delivery of the improved BMP-2-Advanced plasmid DNA within a gene-activated scaffold accelerates mesenchymal stem cell osteogenesis and critical size defect repair.. Journal of Controlled Release. 283, pp. 20-31

  2. Nomikou N, Feichtinger GA, Saha S, Nuernberger S, Heimel P, Redl H, McHale AP. 2018. Ultrasound‐responsive gene‐activated matrices for osteogenic gene therapy using matrix‐assisted sonoporation. Journal of Tissue Engineering and Regenerative Medicine. 12(1), pp. e250-e260

  3. Feichtinger GA, Hofmann AT, Wassermann K, Zimmermann A, van Griensven M, Redl H. 2014. Constitutive and inducible co-expression systems for non-viral osteoinductive gene therapy. European Cells and Materials. 27, pp. 166-184

  4. Odabas S, Feichtinger GA, Korkusuz P, Inci I, Bilgic E, Yar AS, Cavusoglu T, Menevse S, Vargel I, Piskin E. 2013. Auricular cartilage repair using cryogel scaffolds loaded with BMP-7-expressing primary chondrocytes. Journal of Tissue Engineering and Regenerative Medicine. 7(10), pp. 831-840


This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2025 MolecularCloud